07 November 2022 | News
Deploying vaccines with proven efficacy yet unlicensed as part of the outbreak response
image credit- shutterstock
Following the declaration of an Ebola outbreak in Uganda on 20 September 2022, the outbreak has now spread to seven districts (Kasanda, Kyegegwa, Bunyangabu and Kagadi districts beyond the original epicenter in Mubende district, and then to Kampala City and Wakiso).
The Ministry of Health has designated the Makerere University Lung Institute to conduct vaccine and therapeutics clinical trials. The clinical trial to evaluate candidate vaccines against this ebolavirus is co-sponsored by the Ministry of Health in Uganda and WHO, and involves support from partners. A Principal investigator from Makerere University Lung Institute will lead the vaccine trial.
WHO, CEPI and Gavi are providing support to ensure that sufficient doses of candidate vaccines are available for the trial and beyond. If sufficient doses can be made available, the aim of the vaccine trial would be to establish how effective the candidate vaccines are in diverse populations.
The vaccine developers and funders who will make the candidate vaccines available include the University of Oxford and the Serum Institute of India, the Sabin Vaccine Institute and the US government institutions Biomedical Advanced Research and Development Authority (BARDA) and National Institutes of Health (NIH), as well as International AIDS Vaccine Initiative (IAVI) and MSD.